De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer

Masayuki Takeda, Isamu Okamoto, Yoshihiko Fujita, Tokuzo Arao, Hiroyuki Ito, Masahiro Fukuoka, Kazuto Nishio, Kazuhiko Nakagawa

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Background: Somatic mutations in the epidermal growth factor receptor (EGFR) gene are a predictor of response to treatment with EGFR tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). However, mechanisms of de novo resistance to these drugs in patients harboring EGFR mutations have remained unclear. We examined whether the mutational status of KRAS might be associated with primary resistance to EGFR-TKIs in EGFR mutation-positive patients with NSCLC. Methods: Forty patients with NSCLC with EGFR mutations who were treated with gefitinib or erlotinib and had archival tissue specimens available were enrolled in the study. KRAS mutations were analyzed by direct sequencing. Results: Three (7.5%) of the 40 patients had progressive disease, and two (67%) of these three individuals had both KRAS and EGFR mutations. Conclusions: Our Results suggest that KRAS mutation is a negative predictor of response to EGFR-TKIs in EGFR mutation-positive patients with NSCLC.

Original languageEnglish
Pages (from-to)399-400
Number of pages2
JournalJournal of Thoracic Oncology
Volume5
Issue number3
DOIs
Publication statusPublished - Jan 1 2010
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Mutation
erbB-1 Genes
Drug Resistance

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer. / Takeda, Masayuki; Okamoto, Isamu; Fujita, Yoshihiko; Arao, Tokuzo; Ito, Hiroyuki; Fukuoka, Masahiro; Nishio, Kazuto; Nakagawa, Kazuhiko.

In: Journal of Thoracic Oncology, Vol. 5, No. 3, 01.01.2010, p. 399-400.

Research output: Contribution to journalArticle

Takeda, Masayuki ; Okamoto, Isamu ; Fujita, Yoshihiko ; Arao, Tokuzo ; Ito, Hiroyuki ; Fukuoka, Masahiro ; Nishio, Kazuto ; Nakagawa, Kazuhiko. / De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer. In: Journal of Thoracic Oncology. 2010 ; Vol. 5, No. 3. pp. 399-400.
@article{18cb7d7fe45947b6b85ac08b13091369,
title = "De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer",
abstract = "Background: Somatic mutations in the epidermal growth factor receptor (EGFR) gene are a predictor of response to treatment with EGFR tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). However, mechanisms of de novo resistance to these drugs in patients harboring EGFR mutations have remained unclear. We examined whether the mutational status of KRAS might be associated with primary resistance to EGFR-TKIs in EGFR mutation-positive patients with NSCLC. Methods: Forty patients with NSCLC with EGFR mutations who were treated with gefitinib or erlotinib and had archival tissue specimens available were enrolled in the study. KRAS mutations were analyzed by direct sequencing. Results: Three (7.5{\%}) of the 40 patients had progressive disease, and two (67{\%}) of these three individuals had both KRAS and EGFR mutations. Conclusions: Our Results suggest that KRAS mutation is a negative predictor of response to EGFR-TKIs in EGFR mutation-positive patients with NSCLC.",
author = "Masayuki Takeda and Isamu Okamoto and Yoshihiko Fujita and Tokuzo Arao and Hiroyuki Ito and Masahiro Fukuoka and Kazuto Nishio and Kazuhiko Nakagawa",
year = "2010",
month = "1",
day = "1",
doi = "10.1097/JTO.0b013e3181cee47e",
language = "English",
volume = "5",
pages = "399--400",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "3",

}

TY - JOUR

T1 - De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer

AU - Takeda, Masayuki

AU - Okamoto, Isamu

AU - Fujita, Yoshihiko

AU - Arao, Tokuzo

AU - Ito, Hiroyuki

AU - Fukuoka, Masahiro

AU - Nishio, Kazuto

AU - Nakagawa, Kazuhiko

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Background: Somatic mutations in the epidermal growth factor receptor (EGFR) gene are a predictor of response to treatment with EGFR tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). However, mechanisms of de novo resistance to these drugs in patients harboring EGFR mutations have remained unclear. We examined whether the mutational status of KRAS might be associated with primary resistance to EGFR-TKIs in EGFR mutation-positive patients with NSCLC. Methods: Forty patients with NSCLC with EGFR mutations who were treated with gefitinib or erlotinib and had archival tissue specimens available were enrolled in the study. KRAS mutations were analyzed by direct sequencing. Results: Three (7.5%) of the 40 patients had progressive disease, and two (67%) of these three individuals had both KRAS and EGFR mutations. Conclusions: Our Results suggest that KRAS mutation is a negative predictor of response to EGFR-TKIs in EGFR mutation-positive patients with NSCLC.

AB - Background: Somatic mutations in the epidermal growth factor receptor (EGFR) gene are a predictor of response to treatment with EGFR tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). However, mechanisms of de novo resistance to these drugs in patients harboring EGFR mutations have remained unclear. We examined whether the mutational status of KRAS might be associated with primary resistance to EGFR-TKIs in EGFR mutation-positive patients with NSCLC. Methods: Forty patients with NSCLC with EGFR mutations who were treated with gefitinib or erlotinib and had archival tissue specimens available were enrolled in the study. KRAS mutations were analyzed by direct sequencing. Results: Three (7.5%) of the 40 patients had progressive disease, and two (67%) of these three individuals had both KRAS and EGFR mutations. Conclusions: Our Results suggest that KRAS mutation is a negative predictor of response to EGFR-TKIs in EGFR mutation-positive patients with NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=77649288699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649288699&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e3181cee47e

DO - 10.1097/JTO.0b013e3181cee47e

M3 - Article

VL - 5

SP - 399

EP - 400

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 3

ER -